Proposed is a hemostatic sprayer for stopping a flow of blood from a bleeding portion of the human body, the hemostatic sprayer including a powder casing inside which an accommodation space is formed and which includes inlet and outlet ports, hemostatic in the form of powders being pre-stored in the accommodation space, and the inlet and outlet ports connecting thereto, and a receptacle inside which gas is compressed and pre-stored and which has a supply port on one side, the supply port separably connecting to the inlet port, wherein the supply port is open as a result of pressing by the powder casing, wherein, through the open supply port, the gas is supplied with a preset pressure toward the inlet port and flows into the accommodation space through the inlet port, and wherein the gas flowing is discharged together with the hemostatic through the outlet port while scattering the hemostatic.

The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.

Provided herein are settable and non-settable compositions for use in surgical procedures comprising a variety of disclosed particles and optionally including previously unclotted, lyophilized, optionally crosslinked mammalian blood plasma. Also provided are related compositions, including surgical kits and packages, as well as methods of making and using the compositions.

A staple cartridge comprising a tissue thickness compensator is disclosed. The tissue thickness compensator comprises an uncompressed height, a compressed height, an outer encasement, and tubular structures aligned along the longitudinal axis. The tubular structures are configured to collapse when pressure is applied to the tissue thickness compensator by tissue during the firing motion.

Disclosed in the present invention are a preparation method for and a use method of a collagen microfiber hemostatic material. Collagen microfibers are obtained by performing high-speed shearing on a solid collagen material, after the collagen microfibers are dispersed in an aqueous phase, a procoagulant active ingredient modifies the surfaces of the collagen microfibers by means of linking molecules; and a collagen microfiber hemostatic material is obtained by performing high-speed shearing again after freeze drying. The collagen microfiber material can be prepared simply and efficiently by means of high-speed shearing; the biological activity of the collagen material is maintained as much as possible; and the microfibers have a length range of 10-1000 μm and high dispersibility, thus facilitating spray processing. The procoagulant active ingredient can be efficiently and quantitatively loaded on the surfaces of the collagen microfibers by means of the linking molecules to enhance the hemostatic effect of the collagen microfibers. The collagen microfiber hemostatic material prepared in the present invention can be used for hemostasis of a bleeding wound by means of spraying application, thereby achieving the effect of non-contact fixed-point hemostasis.

Systems, devices, compositions, and methods for treating bleeding, for containing blood that has been lost by a subject due to bleeding, and for treating surfaces contaminated with blood or expected to be contaminated with blood are disclosed. The systems, devices, compositions, and methods utilize platelets, platelet-derived materials, or both. The invention includes sprayers, nebulizers, and equivalents, to deliver platelets and/or platelet-derived materials to desired surfaces. Exemplary embodiments include the use of a pressurized sprayer configured to deliver a topical administration of a lyophilized platelet and/or platelet-derived material to a surface.

Systems, methods and kits for treating hemorrhages within cavities are provided. The methods utilize the application of a rapid spike of pressure to the closed cavity, followed by a steady state pressure or pressures.

The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.

Disclosed herein are hemostatic materials and methods of production and use thereof.

Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25% by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.